Molecular pathogenesis of transplacentally induced mouse lung tumors

Experimental Lung Research

Volumn 24, Issue 4, 1998, Pages 557-577

  Miller, Mark Steven ^a   Leone Kabler, Sandra ^a   Rollins, Lisa A ^a   Wessner, Lisa L ^b,c   Fan, Manxia ^b,d   Schaeffer, Dorcas O ^b   McEntee, Michael F ^b   O'Sullivan, M Gerard ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cdkn2a; Fetus; Ki ras 2; Lung cancer; Oncogenes; Retinoblastoma; Tumor suppression genes

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INCIDENCE; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; GENE LOCUS; GENE TARGETING; GENETIC ANALYSIS; LUNG CARCINOGENESIS; LUNG TUMOR; MOUSE; NONHUMAN; ONCOGENE K RAS; PATHOGENESIS; PLACENTAL TRANSFER; POINT MUTATION; PRIORITY JOURNAL; RETINOBLASTOMA; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

EID: 0031804265     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.3109/01902149809087386     Document Type: Conference Paper

References (81)

1. Parker SL, Tong T, Bolden S, and Wingo PA. Cancer Statistics, 1997. CA-Cancer J Clin. 1997;47:5-27.
2. Rice JM. Perinatal period and pregnancy: intervals of high risk for chemical carcinogens. Environ Health Perspect. 1979;29:23-27.
3. Miller MS, Jones AB, Anderson LM. The formation of 3-methylcholanthrene-initiated lung tumors correlates with induction of cytochrome CYPIA1 by the carcinogen in fetal but not adult mice. Toxicol Appl Pharmacol. 1990;104:235-245.
4. Miller MS. Transplacental lung carcinogenesis: a pharmacogenetic mouse model for the modulatory role of cytochrome P450 1A1 on lung cancer. Chem Res Toxicol. 1994;7:471-481.
5. Kellermann G, Shaw C, Luyten-Kellermann M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New Engl J Med. 1973;189:934-937.
6. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res. 1982;42:5030-5037.
7. Petruzzelli S, Camus A-M, Carrozzi L, et al. Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients. Cancer Res. 1988;48:4695-4700.
8. McLemore TL, Adelberg S, Liu MC, et al. Expression of CYPIA1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst. 1990;82:1333-1339.
9. Rojas M, Camus A-M, Alexandrov K, et al. Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking. Carcinogenesis. 1992;13:929-933.
10. Stjernfeldt M, Berglund K, Lindsten J, Ludvigsson J. Maternal smoking during pregnancy and risk of childhood cancer. Lancet. 1986;1:1350-1352.
11. Bunin GR, Kramer S, Marrero O, Meadows AT. Gestational risk factors for Wilms' tumor: results of a case-control study. Cancer Res. 1987;47:2972-2977.
12. Sandler DP, Everson RB, Wilcox AJ, Browder JP. Cancer risk in adulthood from early life exposure to parents' smoking. Am J Public Health. 1985;75:487-492.
13. John EM, Savitz DA, Sandler DP. Prenatal exposure to parents' smoking and childhood cancer. Am J Epidemiol. 1991;133:123-132.
14. Hansen C, Sorensen LD, Asmussen I, Autrup H. Transplacental exposure to tobacco smoke in human-adduct formation in placenta and umbilical cord blood vessels. Teratogenesis, Carcinog Mutagen. 1992;12:51-60.
15. Manchester DK, Weston A, Choi J-S, et al. Detection of benzo[a]pyrene diol epoxide-DNA adducts in human placenta. Proc Natl Acad Sci USA. 1988;85:9243-9247.
16. Manchester DK, Bowman ED, Parker NB, Caporaso NE, Weston A. Determinants of polycyclic aromatic hydrocarbon-DNA adducts in human placenta. Cancer Res. 1992;52:1499-1503.
17. Whyatt RM, Garte SJ, Cosma G, et al. CYP1A1 messenger RNA levels in placental tissue as a biomarker of environmental exposure. Cancer Epidemiol Biomarkers Prev. 1995;4:147-153.
18. Malkinson AM. The genetic basis of susceptibility to lung tumors in mice. Toxicology. 1989;54:241-271.
19. Witschi H. Modulation of lung tumor development in rats, hamsters and mice. Prog Exp Tumor Res. 1991;33:132-153.
20. Malkinson AM. Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res. 1992;52(S):2670s-2676s.
21. Thomas PE, Kouri RE, Hutton JJ. The genetics of aryl hydrocarbon hydroxylase induction in mice: a single gene difference between C57BL/6J and DBA/2J. Biochem Genet. 1972;6:157-168.
22. Gielen JE, Goujon FM, Nebert DW. Genetic regulation of aryl hydrocarbon hydroxylase induction: simple Mendelian expression in mouse tissues in vivo. J Biol Chem. 1972;247:1125-1137.
23. 1-450 by 3-methylcholanthrene. Mol Pharmacol. 1989;35:823-830.
24. Chang C-Y, Smith DR, Prasad VS, Sidman CL, Nebert DW, Puga A. Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. Pharmacogenetics. 1993;3:312-321.
25. Miller MS, Juchau MR, Guengerich FP, Nebert DW, Raucy JL. Drug metabolic enzymes in developmental toxicology. Fundam Appl Toxicol. 1996;34:165-175.
26. Anderson LM, Jones AB, Riggs CW, Ohshima M. Fetal mouse susceptibility to transplacental lung and liver carcinogenesis by 3-methylcholanthrene: positive correlation with responsiveness to inducers of aromatic hydrocarbon metabolism. Carcinogenesis. 1985;6:1389-1393.
27. Miller MS, Jones AB, Chauhan DP, Park SS, Anderson LM. Differential induction of fetal mouse liver and lung cytochromes P-450 by β-naphthoflavone and 3-methylcholanthrene. Carcinogenesis. 1989;10:875-883.
28. Miller MS, Jones AB, Chauhan DP, Anderson LM. Role of the maternal environment in determining susceptibility to transplacentally induced chemical carcinogenesis in mouse fetuses. Carcinogenesis. 1990;11:1979-1984.
29. Wessner LL, Fan M, Schaeffer DO, McEntee MF, Miller MS. Mouse lung tumors exhibit specific Ki-ras mutations following transplacental exposure to 3-methylcholanthrene. Carcinogenesis. 1996;17:1519-1526.
30. Rehm S, Ward JM, Have-Opbroek AAWT, et al. Mouse papillary lung tumors transplacentally induced by N-nitrosoethylurea: evidence for alveolar type II cell origin by comparative light microscopic, ultrastructural, and immunohistochemical studies. Cancer Res. 1988;48:148-160.
31. Faccini JM, Abbott DP, Paulus GJJ. Mouse Histopathology: A Glossary for Use in Toxicity and Carcinogenicity Studies. New York: Elsevier Scientific; 1990:48-62.
32. Conti CJ. Mutations of genes of the ras family in human and experimental tumors. In: Klein-Szanto AJP, Anderson MW, Barrett JC, Slaga TJ, eds. Comparative Molecular Carcinogenesis. New York: Wiley-Liss; 1992:357-378.
33. Carbone DP, Minna JD. The molecular genetics of lung cancer. In: Stollerman GH, LaMont JT, Leonard JJ, Siperstein MD, eds. Advances in Internal Medicine. St. Louis: Mosby Year Book; 1992;37:153-171.
34. Reynolds SH, Wiest JS, Devereux TR, Anderson MW, You M. Protooncogene activation in spontaneously occurring and chemically induced rodent and human lung tumors. In: Klein-Szanto AJP, Anderson MW, Barrett JC, Slaga TJ, eds. Comparative Molecular Carcinogenesis. New York: Wiley-Liss; 1992:303-320, 5738-5741.
35. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991;6:1353-1362.
36. Slebos RJC, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJA, Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst. 1991;83:1024-1027.
37. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 1995;55:1444-1447.
38. Leone-Kabler S, Wessner LL, McEntee MF, D'Agostino RB, Miller MS. Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors. Carcinogenesis. 1997;18:1163-1168.
39. Miller MS, Baxter JL, Moore JW, Lewis JD, Schuller HM. Molecular characterization of neuroendocrine lung tumors induced in hamsters by treatment with nitrosamines and hyperoxia. Int J Oncol. 1994;4:5-12.
40. Wang X, Witschi H. Mutations of the Ki-ras protooncogene in 3-methylcholanthrene and urethan-induced and butylated hydroxytoluene-promotcd lung tumors of strain A/J and SWR mice. Cancer Lett. 1995;91:33-39.
41. Osborne MR, Brookes P, Lee H, Harvey RG. The reaction of a 3-methylcholanthrene diol epoxide with DNA in relation to the binding of 3-methylcholanthrene to the DNA of mammalian cells. Carcinogenesis. 1986;7:1345-1350.
42. Nuzum EO, Malkinson AM, Beer DG. Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. Mol Carcinogen. 1990;3:287-295.
43. Li EE, Heflich RH, Bucci TJ, Manjanatha MG, Blaydes BS, Delclos KB. Relationships of DNA adduct formation, K-ras activating mutations and tumorigenic activities of 6-nitrochrysene and its metabolites in the lungs of CD-1 mice. Carcinogenesis. 1994;15:1377-1385.
44. Finkelstein SD, Sayegh R, Bakker A, Swalsky P. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg. 1993;128:526-532.
45. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. New Engl J Med. 1987;317:929-935.
46. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene. 1993;8:2407-2412,411-418.
47. Li Z-H, Zheng J, Weiss LM, Shibata D. c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol. 1994;144:303-309.
48. Keohavong P, DeMichele MAA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res. 1996;2:411-418
49. Westra WH, Baas IO, Hruban RH, et al. K-ras activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996;56:2224-2228.
50. Rosell R, Monzo M, Pifarre A, et al. Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res. 1996;2:1083-1086.
51. Rodenhuis S, Slebos RJC, Boot AJM, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988;48:5738-5741.
52. Greenblatt MS, Bennet WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
53. Levine AJ. p53, the cellular gatekeeper for growth and cell division. Cell. 1997;88:323-331.
54. Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell. 1997;88:315-321.
55. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
56. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
57. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
58. INK4 gene mediated by an adenovirus vector. Cancer Res. 1995;55:3250-3253.
59. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 1995;375:503-506.
60. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA. 1995;92:6289-6293.
61. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA. 1996;93:4350-4354.
62. INK4a expression in primary lung cancers and cell lines. Cancer Res. 1995;55:505-509.
63. Serrano M, Lee H, Chin L, Cordon-Cardo, C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. 1996; Cell. 85:27-37.
64. INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996;56:3415-3420.
65. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene. 1994;9:3375-3378.
66. Rollins LA, Kabler-Leone S, O'Sullivan MG, Miller MS. Role of tumor suppressor genes in transplacental lung carcinogenesis. Molec Carcinogenesis. 1998;20:177-184.
67. Beenken SW, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res. 1991;19:4747-4752.
68. INK4b genes. Oncogene. 1995;11:635-645.
69. INK4a-β in mouse lung tumor cells. Oncogene. 1996;13:1885-1891.
70. Hegi ME, Devereux TR, Dietrich WF, et al. Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res. 1994;54:6257-6264.
71. INK4a in mouse lung tumors. Carcinogenesis. 1997;18:115-120.
72. INK4a alterations in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumorigenesis. Proc Am Assoc Cancer Res. 1997;38:3135.
73. Re FC, Manenti G, Borrello MG, et al. Multiple molecular alterations in mouse lung tumors. Mol Carcinog. 1992;5:155-160.
74. Ryan J, Barker PE, Nesbitt MN, Ruddle FH. KRAS2 as a genetic marker for lung tumor susceptibility in inbred mice. J Natl Cancer Inst. 1987:79, 1351-1357.
75. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.
76. Purdie CA, Harrison DJ, Peter A, et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene. 1994;9:603-609.
77. Hegi ME, Söderkvist P, Foley JF, et al. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis. 1993;14:803-810.
78. Horio Y, Chen A, Rice P, Roth JA, Malkinson AM, Schrump DS. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinog. 1996;17:217-223.
79. INK4 in human cancer. Proc Natl Acad Sci USA. 1994;91:11045-11049.
80. INK4a. Cell. 1997;88:593-602.
81. Fan J, Bertino JR. K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene. 1997;14:2595-2607.